Malignant Female Reproductive System Neoplasm

subtype

Identifier: CI-CAN-00003157
Entity page: /cancer/malignant-female-reproductive-system-neoplasm ↗
Edges: 7,236

Neighbours: 16 genes1 variants19 drugs10 trials
Drawn: 46 of 46 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Malignant Female Reproductive System Neoplasm approved for …APPROVED_FORderived15 of 24show all (up to 200)
← approved for	Carboplatinsmall molecule FDA (US) · approved · 2025-08-08 · As part of a combination regimen, for the initial treatment of advanced ovarian carcinoma.	—	approved	Ovarian Carcinoma	1	Regulatory	openfda	graph →
← approved for

Malignant Female Reproductive System Neoplasm diagnostic of …DIAGNOSTIC_OF1 of 1
← diagnostic of	PAX8 Expressionexpression	supports	A	Malignant Female Reproductive System Neoplasm	1	Curated	civic	graph →

Malignant Female Reproductive System Neoplasm diagnostic of …DIAGNOSTIC_OF1 of 1

← diagnostic of

PAX8 Expressionexpression

supports

Malignant Female Reproductive System Neoplasm

Curated

Malignant Female Reproductive System Neoplasm altered in cohorts of …ALTERED_INderived15 of 701show all (up to 200)
← altered in cohorts of	ADRM1 45 / 57 cases (79 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	GATA5 45 / 57 cases (79 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	PSMA7 45 / 57 cases (79 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	AHSG 44 / 57 cases (77 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	ARFGEF2 44 / 57 cases (77 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	ATP13A3 44 / 57 cases (77 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	CABLES2 44 / 57 cases (77 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	COL20A1 44 / 57 cases (77 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	FNDC11 44 / 57 cases (77 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	GP5 44 / 57 cases (77 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	HRH3 44 / 57 cases (77 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	KNG1 44 / 57 cases (77 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	LSM14B 44 / 57 cases (77 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	MTG2 44 / 57 cases (77 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	OSBPL2 44 / 57 cases (77 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →

Malignant Female Reproductive System Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 256show all (up to 200)
→ investigated in trials for	Paclitaxelsmall molecule 441 trials (102 active) · roll-up of the cancer and its descendants	—	—	Malignant Female Reproductive System Neoplasm	441	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 379 trials (82 active) · roll-up of the cancer and its descendants	—	—	Malignant Female Reproductive System Neoplasm	379	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 266 trials (62 active) · roll-up of the cancer and its descendants	—	—	Malignant Female Reproductive System Neoplasm	266	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 219 trials (83 active) · roll-up of the cancer and its descendants	—	—	Malignant Female Reproductive System Neoplasm	219	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 163 trials (82 active) · roll-up of the cancer and its descendants	—	—	Malignant Female Reproductive System Neoplasm	163	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 117 trials (26 active) · roll-up of the cancer and its descendants	—	—	Malignant Female Reproductive System Neoplasm	117	Observed	clinicaltrials	graph →
→ investigated in trials for	Topotecansmall molecule 108 trials (15 active) · roll-up of the cancer and its descendants	—	—	Malignant Female Reproductive System Neoplasm	108	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 100 trials (27 active) · roll-up of the cancer and its descendants	—	—	Malignant Female Reproductive System Neoplasm	100	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 97 trials (26 active) · roll-up of the cancer and its descendants	—	—	Malignant Female Reproductive System Neoplasm	97	Observed	clinicaltrials	graph →
→ investigated in trials for	Olaparibsmall molecule 93 trials (40 active) · roll-up of the cancer and its descendants	—	—	Malignant Female Reproductive System Neoplasm	93	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 66 trials (8 active) · roll-up of the cancer and its descendants	—	—	Malignant Female Reproductive System Neoplasm	66	Observed	clinicaltrials	graph →
→ investigated in trials for	Niraparibsmall molecule 62 trials (19 active) · roll-up of the cancer and its descendants	—	—	Malignant Female Reproductive System Neoplasm	62	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 54 trials (28 active) · roll-up of the cancer and its descendants	—	—	Malignant Female Reproductive System Neoplasm	54	Observed	clinicaltrials	graph →
→ investigated in trials for	Filgrastimother 53 trials (1 active) · roll-up of the cancer and its descendants	—	—	Malignant Female Reproductive System Neoplasm	53	Observed	clinicaltrials	graph →
→ investigated in trials for	Chemotherapy 50 trials (22 active) · roll-up of the cancer and its descendants	—	—	Malignant Female Reproductive System Neoplasm	50	Observed	clinicaltrials	graph →

Malignant Female Reproductive System Neoplasm studied in …STUDIED_INderived10 of 6,253show all (up to 200)
→ studied in	NCT01242072Phase 1 · completed Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies · condition mapped CURATED_EXACT · 6,253 trials mapped (1,862 active)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT02345265Phase 2 · active not recruiting Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 6,253 trials mapped (1,862 active)	—	—	Fallopian Tube Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02446600Phase 3 · active not recruiting Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 6,253 trials mapped (1,862 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 6,253 trials mapped (1,862 active)	—	—	Cervical Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02502266Phase 2/Phase 3 · active not recruiting Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 6,253 trials mapped (1,862 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03348631Phase 2 · active not recruiting Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer · condition mapped CURATED_BROADER · 6,253 trials mapped (1,862 active)	—	—	Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05051722recruiting Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer · condition mapped CURATED_BROADER · 6,253 trials mapped (1,862 active)	—	—	Malignant Endometrial Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05242770NA · completed Pelvic Physical Therapy for Sexual Dysfunction in Gynecologic Oncology Survivors · condition mapped ALIAS · 6,253 trials mapped (1,862 active)	—	—	Malignant Female Reproductive System Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 6,253 trials mapped (1,862 active)	—	—	Endometrial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05287451NA · recruiting Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study · condition mapped CURATED_EXACT · 6,253 trials mapped (1,862 active)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains